Terms ending in 2035
Every in-force patent on Oncotherapy Science, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,092,634 | UBE2T Peptides and Vaccines Containing the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 11,266,729 | UBE2T Peptides and Vaccines Containing the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 10,576,097 | URLC10-Derived Peptide and Vaccine Containing Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 10,676,514 | CDCA1-DERIVED Peptide and Vaccine Containing Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.